14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 229-236

  Nakamura, Yukiko ^a   Oshima, Kazuteru ^a   Naoi, Yasuto ^a   Nakayama, Takahiro ^a   Kim, Seung Jin ^a   Shimazu, Kenzo ^a   Shimomura, Atsushi ^a   Maruyama, Naomi ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

14 3 3 ; Breast cancer; Chemotherapy; TP53

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PROTEIN P53; STRATIFIN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PATHOLOGICAL COMPLETE RESPONSE; PRIORITY JOURNAL; STRATIFIN GENE; TP53 GENE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; WILD TYPE;

14-3-3 PROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; EXONUCLEASES; FEMALE; FLUOROURACIL; HUMANS; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PACLITAXEL; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863984506     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1976-x     Document Type: Article

References (35)

1. P Mhawech 2005 14-3-3 proteins-an update Cell Res 15 4 228 236 15857577 10.1038/sj.cr.7290291 1:CAS:528:DC%2BD2MXhtFWntr%2FJ
2. K Horie-Inoue S Inoue 2006 Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers Semin Cancer Biol 16 3 235 239 16682214 10.1016/j.semcancer.2006.03.006 1:CAS:528:DC%2BD28XltlKms7k%3D
3. MH Lee G Lozano 2006 Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins Semin Cancer Biol 16 3 225 234 16697215 10.1016/j.semcancer. 2006.03.009 1:CAS:528:DC%2BD28XltlKms7s%3D
4. H Hermeking A Benzinger 2006 14-3-3 proteins in cell cycle regulation Semin Cancer Biol 16 3 183 192 16697662 10.1016/j.semcancer.2006.03.002 1:CAS:528:DC%2BD28XltlKmsrY%3D
5. PT Simpson T Gale JS Reis-Filho C Jones S Parry D Steele A Cossu M Budroni G Palmieri SR Lakhani 2004 Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue J Pathol 202 3 274 285 14991892 10.1002/path.1530 1:CAS:528:DC%2BD2cXislejsLg%3D
6. S Mirza G Sharma R Parshad A Srivastava SD Gupta R Ralhan 2010 Clinical significance of Stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients Clin Biochem 43 4-5 380 386 19961842 10.1016/j.clinbiochem.2009.11.016 1:CAS:528:DC%2BC3cXit1Wqurk%3D
7. K Ito T Suzuki J Akahira M Sakuma S Saitou S Okamoto H Niikura K Okamura N Yaegashi H Sasano S Inoue 2005 14-3-3sigma in endometrial cancer-a possible prognostic marker in early-stage cancer Clin Cancer Res 11 20 7384 7391 16243811 10.1158/1078-0432.CCR-05-0187 1:CAS:528:DC%2BD2MXhtFartbrE
8. L Cheng CX Pan JT Zhang S Zhang MS Kinch L Li LA Baldridge C Wade Z Hu MO Koch TM Ulbright JN Eble 2004 Loss of 14-3-3sigma in prostate cancer and its precursors Clin Cancer Res 10 9 3064 3068 15131044 10.1158/1078-0432.CCR-03-0652 1:CAS:528:DC%2BD2cXjs12lsbc%3D
9. H Nakayama T Sano A Motegi T Oyama T Nakajima 2005 Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma Pathol Int 55 11 707 715 16271083 10.1111/j.1440-1827.2005.01900.x 1:CAS:528:DC%2BD2MXhtlelu7nL
10. AT Ferguson E Evron CB Umbricht TK Pandita TA Chan H Hermeking JR Marks AR Lambers PA Futreal MR Stampfer S Sukumar 2000 High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer Proc Natl Acad Sci USA 97 11 6049 6054 10811911 10.1073/pnas.100566997 1:CAS:528:DC%2BD3cXjvFartr4%3D
11. CB Umbricht E Evron E Gabrielson A Ferguson J Marks S Sukumar 2001 Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer Oncogene 20 26 3348 3353 11423985 10.1038/sj.onc.1204438 1:CAS:528: DC%2BD3MXltVSqsbY%3D
12. H Simooka T Oyama T Sano J Horiguchi T Nakajima 2004 Immunohistochemical analysis of 14-3-3 sigma and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenesis Pathol Int 54 8 595 602 15260850 10.1111/j.1440-1827.2004.01668.x 1:CAS:528: DC%2BD2cXnslSksLo%3D
13. J Akahira Y Sugihashi T Suzuki K Ito H Niikura T Moriya M Nitta H Okamura S Inoue H Sasano K Okamura N Yaegashi 2004 Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation Clin Cancer Res 10 8 2687 2693 15102672 10.1158/1078-0432.CCR-03-0510 1:CAS:528:DC%2BD2cXjt1CltL8%3D
14. P Mhawech A Benz C Cerato V Greloz M Assaly JC Desmond HP Koeffler D Lodygin H Hermeking F Herrmann J Schwaller 2005 Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation Mod Pathol 18 3 340 348 15257317 10.1038/modpathol.3800240 1:CAS:528:DC%2BD2MXhtlertLY%3D
15. A Perathoner D Pirkebner G Brandacher G Spizzo S Stadlmann P Obrist R Margreiter A Amberger 2005 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients Clin Cancer Res 11 9 3274 3279 15867223 10.1158/1078-0432.CCR-04-2207 1:CAS:528: DC%2BD2MXjslOqsbY%3D
16. D Neupane M Korc 2008 14-3-3sigma Modulates pancreatic cancer cell survival and invasiveness Clin Cancer Res 14 23 7614 7623 19047086 10.1158/1078-0432.CCR-08-1366 1:CAS:528:DC%2BD1cXhsVegtrnI
17. K Tanaka T Hatada M Kobayashi Y Mohri H Tonouchi C Miki T Nobori M Kusunoki 2004 The clinical implication of 14-3-3 sigma expression in primary gastrointestinal malignancy Int J Oncol 25 6 1591 1597 15547695 1:CAS:528:DC%2BD2MXhsVOrsQ%3D%3D
18. R Holm T Ali DH Svendsrud JM Nesland GB Kristensen H Lyng 2009 Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome Oncol Rep 22 1 11 15 19513498 10.3892/or-00000399 1:CAS:528: DC%2BD1MXoslymsrw%3D
19. T Nakajima H Shimooka P Weixa A Segawa A Motegi Z Jian N Masuda M Ide T Sano T Oyama H Tsukagoshi K Hamanaka M Maeda 2003 Immunohistochemical demonstration of 14-3-3 sigma protein in normal human tissues and lung cancers, and the preponderance of its strong expression in epithelial cells of squamous cell lineage Pathol Int 53 6 353 360 12787309 10.1046/j.1440-1827.2003.01481.x 1:CAS:528:DC%2BD3sXmslantrc%3D
20. CD Logsdon DM Simeone C Binkley T Arumugam JK Greenson TJ Giordano DE Misek R Kuick S Hanash 2003 Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer Cancer Res 63 10 2649 2657 12750293 1:CAS:528: DC%2BD3sXjsleht7Y%3D
21. A Guweidhi J Kleeff N Giese J El Fitori K Ketterer T Giese MW Buchler M Korc H Friess 2004 Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis Carcinogenesis 25 9 1575 1585 15073049 10.1093/carcin/bgh159 1:CAS:528:DC%2BD2cXntFaitbw%3D
22. Y Liu H Liu B Han JT Zhang 2006 Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis Cancer Res 66 6 3248 3255 16540677 10.1158/0008-5472.CAN-05- 3801 1:CAS:528:DC%2BD28Xitlert7c%3D
23. B Han H Xie Q Chen JT Zhang 2006 Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma Mol Cancer Ther 5 4 903 912 16648560 10.1158/1535-7163.MCT-05-0393 1:CAS:528:DC%2BD28XjvFCktr0%3D
24. P Sinha G Hutter E Kottgen M Dietel D Schadendorf H Lage 1999 Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas Electrophoresis 20 14 2952 2960 10546833 10.1002/(SICI)1522-2683(19991001)20: 14<2952::AID-ELPS2952>3.0.CO;2-H 1:CAS:528:DyaK1MXmvFahtrg%3D
25. ML Gehrmann C Fenselau Y Hathout 2004 Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line J Proteome Res 3 3 403 409 15253420 10.1021/pr0340577 1:CAS:528:DC%2BD3sXps1WgsbY%3D
26. ML Gehrmann Y Hathout C Fenselau 2004 Evaluation of metabolic labeling for comparative proteomics in breast cancer cells J Proteome Res 3 5 1063 1068 15473696 10.1021/pr049906k 1:CAS:528:DC%2BD2cXmslaqtLw%3D
27. JM Moreira G Ohlsson FE Rank JE Celis 2005 Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast Mol Cell Proteomics 4 4 555 569 15644556 10.1074/mcp.M400205-MCP200 1:CAS:528:DC%2BD2MXjtFCisbo%3D
28. T Iwamoto N Yamamoto T Taguchi Y Tamaki S Noguchi 2011 BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation Breast Cancer Res Treat 129 1 69 77 20882403 10.1007/s10549-010-1188-1 1:CAS:528:DC%2BC3MXptVOisb4%3D
29. A Shimomura Y Miyoshi T Taguchi Y Tamaki S Noguchi 2009 Association of loss of BRCA1 expression with centrosome aberration in human breast cancer J Cancer Res Clin Oncol 135 3 421 430 18813953 10.1007/s00432-008-0472-5 1:CAS:528:DC%2BD1MXht1Ogu7Y%3D
30. T Tanei K Morimoto K Shimazu SJ Kim Y Tanji T Taguchi Y Tamaki S Noguchi 2009 Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers Clin Cancer Res 15 12 4234 4241 19509181 10.1158/1078-0432.CCR-08-1479 1:CAS:528:DC%2BD1MXntlOitrw%3D
31. HJ Bloom WW Richardson 1957 Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years Br J Cancer 11 3 359 377 13499785 10.1038/bjc.1957.43 1:STN:280: DyaG1c%2Fkt1Gmtg%3D%3D
32. K Oshima Y Naoi K Kishi Y Nakamura T Iwamoto K Shimazu T Nakayama SJ Kim Y Baba Y Tamaki S Noguchi 2011 Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer Cancer Lett 307 2 149 157 21514041 10.1016/j.canlet.2011.03.027 1:CAS:528:DC%2BC3MXmslOmsr8%3D
33. T Urano T Saito T Tsukui M Fujita T Hosoi M Muramatsu Y Ouchi S Inoue 2002 Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth Nature 417 6891 871 875 12075357 10.1038/nature00826 1:CAS:528: DC%2BD38Xks1Wmu7g%3D
34. H Suzuki F Itoh M Toyota T Kikuchi H Kakiuchi K Imai 2000 Inactivation of the 14-3-3 sigma gene is associated with 5 CpG island hypermethylation in human cancers Cancer Res 60 16 4353 4357 10969776 1:CAS:528:DC%2BD3cXmsVaiuro%3D
35. Z Wang CG Trope Z Suo G Troen G Yang JM Nesland R Holm 2008 The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas BMC Cancer 8 308 18950492 10.1186/1471-2407-8-308